Abstract
A tumor active targeting β-cyclodextrin based nanocarrier β-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives β-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy.
MeSH terms
-
Animals
-
Cyclodextrins / chemistry*
-
Drug Delivery Systems*
-
Drug Resistance, Neoplasm*
-
Folic Acid / chemistry*
-
Genetic Therapy
-
HeLa Cells
-
Hep G2 Cells
-
Humans
-
Mice
-
Molecular Structure
-
Nanoparticles*
-
Neoplasms / therapy*
-
Nuclear Receptor Subfamily 4, Group A, Member 1 / genetics
-
Paclitaxel / administration & dosage
-
Proto-Oncogene Proteins c-bcl-2 / metabolism
-
Transfection
-
Xenograft Model Antitumor Assays
Substances
-
BCL2 protein, human
-
Cyclodextrins
-
Nuclear Receptor Subfamily 4, Group A, Member 1
-
Proto-Oncogene Proteins c-bcl-2
-
Folic Acid
-
Paclitaxel